Antibody Discovery Benchmark: 100 evals to test AI agents' scientific decisions across drug discovery
kenbwork · x · 2026-09-03
A new Antibody Discovery Benchmark tests whether AI agents can make sound scientific decisions across therapeutic antibody discovery: 100 evaluations across ten areas from real drug programs, including target/modality selection, assay design, binder discovery, binding characterization, cellular pharmacology, antibody engineering, and preclinical de-risking. It emphasizes that antibody discovery is multiparameter and context-dependent—display enrichment can reflect amplification bias rather than binding, and strong binding to purified antigen may not translate to native cell-surface recognition.
More from Research
- Genomics researcher calls out popular benchmarks as opaque and flawed — anshulkundaje · 2026-09-03
- Expert: many popular genomics benchmarks are deeply flawed — publish their limits — anshulkundaje · 2026-09-03
- Untrained networks already tell cats from dogs: architectures as evolutionary selection — joannejang · 2026-09-03
- Stanford Prof. Anshul Kundaje: most public benchmarks in his field are badly biased — anshulkundaje · 2026-09-03
- CS professor builds AI system to preserve endangered languages and create new ones — begusgasper · 2026-09-03
- Cosmos Institute funds 80 grantees building AI for human autonomy and truth-seeking — hunarbatra · 2026-09-03